‘The sleeping giant is waking up’: FTC raises the pressure on pharma dealmaking

In 2020, the Federal Trade Commission narrowly approved AbbVie’s $65 billion takeover of Allergan. It’s unlikely the antitrust enforcer would approve such a deal today.

The commission’s approval was accompanied by a 20-page dissent from then-Commissioner Rohit Chopra, who criticized the FTC’s handling of the merger and others like it….
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks